ReviewImmunology and cell biology
Cystatin C is a disease-associated protein subject to multiple regulation.
Review in Immunology and cell biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.
- Serum creatinine/cystatin C ratio as a muscle mass evaluating tool and prognostic indicator for hospitalized patients: A meta-analysis.Frontiers in medicine · 2022Pooled it
- Estimated glomerular filtration rate discordance and cardiopulmonary morbidity in sickle cell disease.Blood advances · 2026Article
- Article
- Novel Plasma Proteomic Markers and Risk of Venous Thromboembolism.Circulation · 2026Article
- Article
- Mendelian Randomization to Examine the Causal Effects of Cystatin on Ovarian Lesions.International journal of women's health · 2026Article
- Long-term cystatin C trajectories and cognitive decline in diabetes and non-diabetes: evidence from a national Chinese cohort.Frontiers in medicine · 2026Article
- Cancer Hacks Neurodegeneration: Cystatin-C as a Bridge for Microglial Amyloid Clearance via TREM2.Research (Washington, D.C.) · 2026Article
- Translational advances in diabetic nephropathy management: integrating nanoformulation-based drug delivery systems.Frontiers in medical technology · 2026Review
- Age-related decline in protein turnover highlights cystatin C dysfunction and links proteostasis collapse to neuroinflammation in the murine cortex.Biogerontology · 2025Article
- Recent advancements in patented technologies for the diagnosis and treatment of chronic kidney disease.International urology and nephrology · 2025Review
- Mechanisms of exercise in preventing cardiovascular diseases: Insights from gut microbiota characteristics in pathological states of cardiovascular diseases.Reviews in endocrine & metabolic disorders · 2025Review
- Cadmium exposure, epigenetic modifications, and serum cystatin C: insights into mediated pathways and mortality risks in U.S. adults.Clinical epigenetics · 2025Article
- Gadoteric Acid and Gadolinium: Exploring Short- and Long-Term Effects on Healthy Animals.Journal of xenobiotics · 2025Article
- [High serum cystatin C is an independent risk factor for poor renal prognosis in IgA nephropathy].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- Diagnostic value of serum TGF-β1 and CysC in type 2 diabetic kidney disease: a cross-sectional study.Frontiers in medicine · 2025Article
- Associations of Serum Cystatin C, DNAm Cystatin C, Renal Function, and Mortality in U.S. Adults.Life (Basel, Switzerland) · 2024Article
- Menaquinone-7 and its therapeutic potential in type 2 diabetes mellitus based on a Zucker diabetic fatty rat model.Heliyon · 2024Article
- Sex difference in the association between creatinine-to-cystatin C ratio and metabolic syndrome among Chinese adults.Frontiers in endocrinology · 2024Article
- Preoperative Serum Cystatin C as an Independent Prognostic Factor for Survival in Patients with Renal Cell Carcinoma.Journal of Cancer · 2024Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A protease inhibitor, cystatin C (Cst C), is a secreted cysteine protease inhibitor abundantly expressed in body fluids. Clinically, it is mostly used to measure glomerular filtration rate as a marker for kidney function due to its relatively small molecular weight and easy detection. However, recent findings suggest that Cst C is regulated at both transcriptional and post-translational levels, and Cst C production from haematopoietic cell lineages contributes significantly to the systematic pools of Cst C. Furthermore, Cst C is directly linked to many pathologic processes through various mechanisms. Thus fluctuation of Cst C levels might have serious clinical implications rather than a mere reflection of kidney functions. Here, we summarize the pathophysiological roles of Cst C dependent and independent on its inhibition of proteases, outline its change of expression by various stimuli, and elucidate the regulatory mechanisms to control this disease-related protease inhibitor. Finally, we discuss the clinical implications of these findings for translational gains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.